$ACAD
ACADIA PHARMACEUTICALS INC

2022 Q3 Form 10-Q Financial Statement

#000095017022015642 Filed on August 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $130.7M $134.6M $115.5M
YoY Change -0.68% 16.79% 8.37%
Cost Of Revenue $2.136M $2.667M $2.950M
YoY Change -68.03% 5.58% 35.01%
Gross Profit $128.6M $131.9M $112.5M
YoY Change 0.51% 17.04% 7.81%
Gross Profit Margin 98.37% 98.02% 97.45%
Selling, General & Admin $78.11M $89.90M $96.68M
YoY Change -4.36% -7.12% -13.42%
% of Gross Profit 60.75% 68.16% 85.92%
Research & Development $81.34M $75.65M $128.9M
YoY Change 38.88% 32.86% 126.17%
% of Gross Profit 63.26% 57.35% 114.52%
Depreciation & Amortization $506.0K $515.0K $516.0K
YoY Change -48.63% -44.26% -1.71%
% of Gross Profit 0.39% 0.39% 0.46%
Operating Expenses $159.4M $165.5M $225.5M
YoY Change 13.7% 7.69% 33.74%
Operating Profit -$30.87M -$33.65M -$113.0M
YoY Change 150.8% -23.01% 69.26%
Interest Expense $2.295M $580.0K $105.0K
YoY Change 1679.07% 336.09% -47.5%
% of Operating Profit
Other Income/Expense, Net $2.156M -$497.0K $340.0K
YoY Change 462.92% -379.21% -334.48%
Pretax Income -$26.42M -$33.57M -$112.6M
YoY Change 78.61% -22.65% 69.47%
Income Tax $768.0K $443.0K $485.0K
% Of Pretax Income
Net Earnings -$27.18M -$34.01M -$113.1M
YoY Change 88.03% -22.47% 70.14%
Net Earnings / Revenue -20.8% -25.28% -97.91%
Basic Earnings Per Share -$0.17 -$0.21 -$0.70
Diluted Earnings Per Share -$0.17 -$0.21 -$701.2K
COMMON SHARES
Basic Shares Outstanding 161.8M 161.7K 161.2M
Diluted Shares Outstanding 161.9K 161.7K 161.2M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $436.6M $436.4M $446.0M
YoY Change -19.2% -21.65% -22.81%
Cash & Equivalents $154.8M $139.8M $204.9M
Short-Term Investments $281.7M $296.5M $241.1M
Other Short-Term Assets $22.99M $20.95M $25.76M
YoY Change -6.62% -20.05% -9.63%
Inventory $11.84M $12.53M $13.21M
Prepaid Expenses $22.99M $20.95M $25.76M
Receivables $55.73M $67.95M $62.71M
Other Receivables $403.0K $936.0K $769.0K
Total Short-Term Assets $521.6M $532.5M $542.2M
YoY Change -18.62% -17.53% -19.55%
LONG-TERM ASSETS
Property, Plant & Equipment $6.510M $7.016M $7.531M
YoY Change -90.51% -90.06% -89.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.043M $3.839M $4.336M
YoY Change 154.66% -50.54% -42.95%
Total Long-Term Assets $80.94M $80.25M $82.03M
YoY Change 5.45% 1.97% 1.02%
TOTAL ASSETS
Total Short-Term Assets $521.6M $532.5M $542.2M
Total Long-Term Assets $80.94M $80.25M $82.03M
Total Assets $602.5M $612.8M $624.3M
YoY Change -16.05% -15.41% -17.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.01M $11.85M $10.77M
YoY Change 29.6% 30.77% 22.36%
Accrued Expenses $106.6M $105.8M $108.8M
YoY Change 32.38% 22.68% 8.27%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $116.6M $117.7M $119.6M
YoY Change 32.14% 23.45% 9.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.466M $5.544M $4.373M
YoY Change -89.65% -91.37% -93.19%
Total Long-Term Liabilities $6.466M $5.544M $4.373M
YoY Change -89.65% -91.37% -93.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $116.6M $117.7M $119.6M
Total Long-Term Liabilities $6.466M $5.544M $4.373M
Total Liabilities $176.8M $177.9M $179.5M
YoY Change 17.31% 11.48% 3.37%
SHAREHOLDERS EQUITY
Retained Earnings -$2.328B -$2.301B -$2.267B
YoY Change
Common Stock $2.755B $2.736B $2.712B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $425.7M $434.8M $444.8M
YoY Change
Total Liabilities & Shareholders Equity $602.5M $612.8M $624.3M
YoY Change -16.05% -15.41% -17.34%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$27.18M -$34.01M -$113.1M
YoY Change 88.03% -22.47% 70.14%
Depreciation, Depletion And Amortization $506.0K $515.0K $516.0K
YoY Change -48.63% -44.26% -1.71%
Cash From Operating Activities -$727.0K -$13.13M -$76.33M
YoY Change -95.74% -48.18% 26.9%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $15.44M -$55.80M $131.3M
YoY Change -109.88% 225.18% 311.1%
Cash From Investing Activities $15.44M -$55.80M $131.3M
YoY Change -109.88% 224.21% 325.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.467M
YoY Change -68.07%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 287.0K 3.831M 2.467M
YoY Change -73.08% -23.4% -68.07%
NET CHANGE
Cash From Operating Activities -727.0K -13.13M -76.33M
Cash From Investing Activities 15.44M -55.80M 131.3M
Cash From Financing Activities 287.0K 3.831M 2.467M
Net Change In Cash 15.00M -65.09M 57.49M
YoY Change -108.71% 73.41% -366.86%
FREE CASH FLOW
Cash From Operating Activities -$727.0K -$13.13M -$76.33M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$727.0K -$13.13M -$76.33M
YoY Change -95.74% -48.09% 24.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2022Q2 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
dei Amendment Flag
AmendmentFlag
false
CY2021Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2022Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001070494
CY2021Q2 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-50768
dei Entity Registrant Name
EntityRegistrantName
ACADIA PHARMACEUTICALS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
06-1376651
dei Entity Address Address Line1
EntityAddressAddressLine1
12830 El Camino Real, Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Local Phone Number
LocalPhoneNumber
558-2871
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
dei City Area Code
CityAreaCode
858
dei Trading Symbol
TradingSymbol
ACAD
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
161843185
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
139833000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
147435000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
296518000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
373271000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
67953000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
64366000
CY2022Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
936000
CY2021Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
978000
CY2022Q2 acad Short Term Inventory
ShortTermInventory
6327000
CY2021Q4 acad Short Term Inventory
ShortTermInventory
7881000
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
20952000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
23892000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
532519000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
617823000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7016000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8047000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
57417000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
58268000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2022Q2 us-gaap Inventory For Long Term Contracts Or Programs
InventoryForLongTermContractsOrPrograms
6205000
CY2021Q4 us-gaap Inventory For Long Term Contracts Or Programs
InventoryForLongTermContractsOrPrograms
6217000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3839000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3997000
CY2022Q2 us-gaap Assets
Assets
612766000
CY2021Q4 us-gaap Assets
Assets
700122000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
11854000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6876000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
105827000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
89192000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
117681000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
96068000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
54693000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
56126000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5544000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7034000
CY2022Q2 us-gaap Liabilities
Liabilities
177918000
CY2021Q4 us-gaap Liabilities
Liabilities
159228000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
161842369
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
161842369
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
161012695
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
161012695
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
16000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
16000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2736318000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2694646000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2300643000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2153576000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-843000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-192000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
434848000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
540894000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
612766000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
700122000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
134563000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
115221000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
250031000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
221775000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
134563000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
115221000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
250031000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
221775000
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2667000
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2526000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5617000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4711000
CY2021Q2 acad License Fees And Royalty Expense
LicenseFeesAndRoyaltyExpense
2680000
acad License Fees And Royalty Expense
LicenseFeesAndRoyaltyExpense
5187000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
75646000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56935000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
204501000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
113908000
us-gaap Net Income Loss
NetIncomeLoss
-147067000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
89901000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
96789000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
186580000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
208450000
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
168214000
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
158930000
us-gaap Costs And Expenses
CostsAndExpenses
396698000
us-gaap Costs And Expenses
CostsAndExpenses
332256000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-33651000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-43709000
us-gaap Operating Income Loss
OperatingIncomeLoss
-146667000
us-gaap Operating Income Loss
OperatingIncomeLoss
-110481000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
580000
CY2021Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
133000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
685000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
333000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-497000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
178000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-157000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
323000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33568000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43398000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-146139000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-109825000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
443000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
473000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
928000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
494000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-34011000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-43871000
us-gaap Net Income Loss
NetIncomeLoss
-147067000
us-gaap Net Income Loss
NetIncomeLoss
-110319000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
161654
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
161654
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
160421
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
160421
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
161443
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
161443
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
160217
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
160217
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-34011000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-43871000
us-gaap Depreciation
Depreciation
1085000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3587000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3120000
us-gaap Net Income Loss
NetIncomeLoss
-110319000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-236000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
5000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-658000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
7000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34242000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43867000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-147718000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-110317000
us-gaap Profit Loss
ProfitLoss
-147067000
us-gaap Profit Loss
ProfitLoss
-110319000
us-gaap Share Based Compensation
ShareBasedCompensation
35475000
us-gaap Share Based Compensation
ShareBasedCompensation
35189000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-547000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1176000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
739000
us-gaap Gain Loss On Investments
GainLossOnInvestments
-158000
us-gaap Gain Loss On Investments
GainLossOnInvestments
323000
us-gaap Depreciation
Depreciation
1031000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-42000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-1582000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1465000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
878000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-2940000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
512000
acad Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-3172000
acad Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-3289000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-9000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4978000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
572000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
16854000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-11331000
acad Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3972000
acad Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2583000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1490000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-51000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-89454000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-85476000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
125377000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
202526000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
200925000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
217317000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1121000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
75548000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13670000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6298000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12731000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6298000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12731000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7602000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-59072000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
153205000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
331798000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
145603000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
272726000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
444797000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
581606000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
540894000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
627009000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
434848000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
564838000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
434848000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
564838000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20512000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22005000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
35475000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
35189000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
147435000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
139833000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
326028000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
266956000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
153205000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
145603000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
331798000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
272726000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21646000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19489000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8304000
CY2022Q2 acad Accrued Sales Allowances Current
AccruedSalesAllowancesCurrent
14237000
CY2022Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2081000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1114000
CY2022Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
4246000
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
6767000
CY2022Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
6205000
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
6217000
CY2022Q2 us-gaap Inventory Net
InventoryNet
12532000
CY2021Q4 us-gaap Inventory Net
InventoryNet
14098000
CY2022Q2 acad Short Term Inventory
ShortTermInventory
6327000
CY2021Q4 acad Short Term Inventory
ShortTermInventory
7881000
CY2022Q2 us-gaap Inventory For Long Term Contracts Or Programs
InventoryForLongTermContractsOrPrograms
6205000
CY2021Q4 us-gaap Inventory For Long Term Contracts Or Programs
InventoryForLongTermContractsOrPrograms
6217000
CY2022Q2 us-gaap Inventory Net
InventoryNet
12532000
CY2021Q4 us-gaap Inventory Net
InventoryNet
14098000
CY2022Q2 acad Accrued Clinical Development Services Current
AccruedClinicalDevelopmentServicesCurrent
39767000
CY2021Q4 acad Accrued Clinical Development Services Current
AccruedClinicalDevelopmentServicesCurrent
27270000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
23351000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
25896000
CY2021Q4 acad Accrued Sales Allowances Current
AccruedSalesAllowancesCurrent
15717000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
11441000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
9319000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9024000
CY2022Q2 acad Debt Securities And Equity Securities Fv Ni Amortized Cost
DebtSecuritiesAndEquitySecuritiesFvNiAmortizedCost
297369000
CY2022Q2 acad Accrued Branded Prescription Drug Fees Current
AccruedBrandedPrescriptionDrugFeesCurrent
7021000
CY2021Q4 acad Accrued Branded Prescription Drug Fees Current
AccruedBrandedPrescriptionDrugFeesCurrent
1959000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
986000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
727000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
105827000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
89192000
CY2022Q2 acad Debt Securities And Equity Securities Fv Ni Unrealized Gains
DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedGains
32000
CY2022Q2 acad Debt Securities And Equity Securities Fv Ni Unrealized Losses
DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedLosses
883000
CY2022Q2 acad Debt Securities And Equity Securities Fv Ni
DebtSecuritiesAndEquitySecuritiesFvNi
296518000
CY2021Q4 acad Debt Securities And Equity Securities Fv Ni Amortized Cost
DebtSecuritiesAndEquitySecuritiesFvNiAmortizedCost
373475000
CY2021Q4 acad Debt Securities And Equity Securities Fv Ni Unrealized Gains
DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedGains
9000
CY2021Q4 acad Debt Securities And Equity Securities Fv Ni Unrealized Losses
DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedLosses
213000
CY2021Q4 acad Debt Securities And Equity Securities Fv Ni
DebtSecuritiesAndEquitySecuritiesFvNi
373271000
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
43
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
39
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
270873000
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
883000
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
270873000
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
883000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
290997000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
213000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
290997000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
213000
CY2022Q2 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
417886000
CY2022Q2 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
694000
CY2021Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
499785000
CY2021Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
603000
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
603000
acad Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Vesting Of Awards
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityVestingOfAwards
1153000
acad Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Expense Forfeited
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExpenseForfeited
-55000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-1007000
CY2022Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
694000
CY2022Q2 acad Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
36642000
CY2021Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
17377000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
76116000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12399000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
63717000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y4M24D
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2321000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
17377000
CY2021Q4 us-gaap Deferred Compensation Arrangement With Individual Cash Award Granted Amount
DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount
15100000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
4400000
CY2022Q2 us-gaap Deferred Compensation Arrangement With Individual Cash Award Granted Amount
DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount
13300000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
2100000
CY2022Q2 acad Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Expense Recorded
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExpenseRecorded
-800000
acad Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Expense Recorded
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExpenseRecorded
100000
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company leases facilities and certain equipment under noncancelable operating leases with remaining lease terms of 1.5 years to 8.9 years, some of which include options to extend for up to two five-year terms.
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
some of which include options to extend for up to two five-year terms.
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1737000
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
2624000
us-gaap Operating Lease Cost
OperatingLeaseCost
3848000
us-gaap Operating Lease Cost
OperatingLeaseCost
5002000
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
2285000
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
696000
us-gaap Operating Lease Payments
OperatingLeasePayments
4428000
us-gaap Operating Lease Payments
OperatingLeasePayments
1710000
CY2022Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
881000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
8655000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8735000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
8099000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9024000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8304000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
54693000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
56126000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
63717000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
64430000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
4608000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
9377000
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.044
CY2020Q3 acad Capitalization Of Right Of Use Asset
CapitalizationOfRightOfUseAsset
40300000
CY2020Q3 acad Capitalization Of Lease Liability
CapitalizationOfLeaseLiability
40300000
CY2022Q2 acad Capitalization Of Right Of Use Asset
CapitalizationOfRightOfUseAsset
19200000
CY2022Q2 acad Capitalization Of Lease Liability
CapitalizationOfLeaseLiability
19200000

Files In Submission

Name View Source Status
0000950170-22-015642-index-headers.html Edgar Link pending
0000950170-22-015642-index.html Edgar Link pending
0000950170-22-015642.txt Edgar Link pending
0000950170-22-015642-xbrl.zip Edgar Link pending
acad-20220630.htm Edgar Link pending
acad-20220630.xsd Edgar Link pending
acad-20220630_def.xml Edgar Link unprocessable
acad-20220630_lab.xml Edgar Link unprocessable
acad-20220630_pre.xml Edgar Link unprocessable
acad-20220630_htm.xml Edgar Link completed
acad-ex10_1.htm Edgar Link pending
acad-ex31_1.htm Edgar Link pending
acad-ex31_2.htm Edgar Link pending
acad-ex32_1.htm Edgar Link pending
acad-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
acad-20220630_cal.xml Edgar Link unprocessable